Journal: Frontiers in Veterinary Science

Article Title: Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

doi: 10.3389/fvets.2020.580735

Figure Lengend Snippet: Mean plasma pantoprazole concentration (logarithmic scale) vs. time (hr) profiles for neonatal calves ( n = 9) following intravenous (IV) single dose administration of 1.0 mg/kg of pantoprazole.

Article Snippet: Pantoprazole sulfone (Toronto Research Chemicals, Ontario, Canada) became the analyte spiked into blank tissue samples to generate calibration spikes and QC samples.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Frontiers in Veterinary Science

Article Title: Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

doi: 10.3389/fvets.2020.580735

Figure Lengend Snippet: Pantoprazole pharmacokinetic parameters following a single intravenous (1 mg/kg) administration to neonatal Holstein calves.

Article Snippet: Pantoprazole sulfone (Toronto Research Chemicals, Ontario, Canada) became the analyte spiked into blank tissue samples to generate calibration spikes and QC samples.

Techniques:

Journal: Frontiers in Veterinary Science

Article Title: Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

doi: 10.3389/fvets.2020.580735

Figure Lengend Snippet: Tissue concentrations of pantoprazole sulfone (μg/g) in collected tissues 1, 3, and 5 days after intravenous administration of pantoprazole (1 mg/kg) from study calves.

Article Snippet: Pantoprazole sulfone (Toronto Research Chemicals, Ontario, Canada) became the analyte spiked into blank tissue samples to generate calibration spikes and QC samples.

Techniques:

Journal: Frontiers in Veterinary Science

Article Title: Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

doi: 10.3389/fvets.2020.580735

Figure Lengend Snippet: Comparisons of pharmacokinetic parameters of pantoprazole in domestic animal species, after single dose intravenous administration.

Article Snippet: Pantoprazole sulfone (Toronto Research Chemicals, Ontario, Canada) became the analyte spiked into blank tissue samples to generate calibration spikes and QC samples.

Techniques:

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Reply to the Comment on "The m6A Reader IGF2BP2 Regulates Macrophage Phenotypic Activation and Inflammatory Diseases by Stabilizing TSC1 and PPARγ".

doi: 10.1002/advs.202201452

Figure Lengend Snippet: Figure 1. IGF2BP2 expression in LPS activated human macrophages. A) IGF2BP2 mRNA level in HMDMs treated by saline (Control) or LPS (100 ng mL−1) at indicated time. B) IGF2BP2 protein expression in HMDMs treated by normal saline or LPS (100 ng mL−1) for 4 and 8 h. C) Statistically analysis of (B). D) IGF2BP2 protein expression in HMDMs treated by saline or LPS (100 ng mL−1) for 24, 36, and 48 h. E) Statistically analysis of (D). F–I) Inflammatory cytokine and TSC1 mRNA level in HMDMs determined by RT-qPCR after normal saline or LPS treatment at indicated time points; qPCR biological replicates come from six different donors; western blot biological replicates come from three different donors; anti-IGF2BP2 antibody was purchased from Proteintech (11601-1-AP). The mRNA levels in the Control group were set to 1 and levels in others experimental conditions were relative to that after normalization with GAPDH. The dates were shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, versus the control group. p-values were determined by using two-way analysis of variance (ANOVA).

Article Snippet: F–I) Inflammatory cytokine and TSC1 mRNA level in HMDMs determined by RT-qPCR after normal saline or LPS treatment at indicated time points; qPCR biological replicates come from six different donors; western blot biological replicates come from three different donors; anti-IGF2BP2 antibody was purchased from Proteintech (11601-1-AP).

Techniques: Expressing, Saline, Control, Quantitative RT-PCR, Western Blot

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Article Title: Reply to the Comment on "The m6A Reader IGF2BP2 Regulates Macrophage Phenotypic Activation and Inflammatory Diseases by Stabilizing TSC1 and PPARγ".

doi: 10.1002/advs.202201452

Figure Lengend Snippet: Figure 2. IGF2BP2 expression in LPS activated mouse macrophages. A) IGF2BP2 mRNA level in BMDMs treated by saline (Control) or LPS (100 ng mL−1) at the indicated time. B) IGF2BP2 protein expression in BMDMs treated by normal saline or LPS (100 ng mL−1) at the indicated time points, anti-IGF2BP2 antibody was purchased from Proteintech (11601- 1-AP); qPCR and western blot biological replicates from three different donors; IGF2BP2 mRNA levels in Control group were set to 1 and levels in others experimental conditions were relative to that after normalization with GAPDH. The dates were shown as mean ± SEM. *p < 0.05, **p < 0.01, versus the Control group. p-values were determined by using a two- way analysis of variance (ANOVA).

Article Snippet: F–I) Inflammatory cytokine and TSC1 mRNA level in HMDMs determined by RT-qPCR after normal saline or LPS treatment at indicated time points; qPCR biological replicates come from six different donors; western blot biological replicates come from three different donors; anti-IGF2BP2 antibody was purchased from Proteintech (11601-1-AP).

Techniques: Expressing, Saline, Control, Western Blot

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 1 The expression of IGF2BP3 was related to progression and COG risk in NB patients. A Differential expression of m6A methylation regulators between subgroups stratified by progression (N: non-progression; P: progression) in dataset GSE49711. B Differential expression of m6A methylation regulators between subgroups stratified by COG risk (Children’s Oncology Group risk stratification) in dataset GSE49711. C Univariate Cox regression analysis evaluating independently predictive ability of m6A methylation regulators for overall survival of NB patients in TARGET databases. D IGF2BP3 expression level in progression and non-progression NB patients of dataset GSE49711. E IGF2BP3 expression level in high COG risk and nonhigh COG risk NB patients of dataset GSE49711. F The expression levels of IGF2BP3 and MYCN were positively correlated.

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Expressing, Quantitative Proteomics, Methylation

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 2 IGF2BP3 is upregulated in MYCN-amplified NB tissues and cell lines. A Immunohistochemistry images of IGF2BP3 in MYCN-amplified and non-MYCN-amplified NB tissues (n = 35). B The expression level of IGF2BP3 in MYCN-amplified tissues was higher than that in non-MYCN- amplified tissues (n = 35). C qRT-PCR analysis of the expression level of IGF2BP3 in NB cell lines. D Western blot analysis of the expression level of IGF2BP3 in NB cell lines (n = 3).

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Immunohistochemistry, Expressing, Quantitative RT-PCR, Western Blot

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 3 Knockdown of IGF2BP3 inhibited N-myc expression in MYCN-amplified NB cells. A qRT-PCR analysis of the expression level of IGF2BP3 mRNA in SK-N-BE(2) (n = 3); B qRT-PCR analysis of the expression level of MYCN mRNA in SK-N-BE(2) (n = 3); C qRT-PCR analysis of the expression level of IGF2BP3 mRNA in BE(2)-C (n = 3); D qRT-PCR analysis of the expression level of MYCN mRNA in BE(2)-C (n = 3); E RNA-FISH and immunofluorescence analysis of the expression level of MYCN mRNA and IGF2BP3 in SK-N-BE(2) (Green: MYCN mRNA; Red: IGF2BP3 protein; Blue: DAPI); F RNA-FISH and immunofluorescence analysis of the expression level of MYCN mRNA and IGF2BP3 in BE(2)-C (Green: MYCN mRNA; Red: IGF2BP3 protein; Blue: DAPI).

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Knockdown, Expressing, Quantitative RT-PCR

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 4 Knockdown of IGF2BP3 repressed proliferation of MYCN-amplified NB cells. A Monolayer colonies were detected in SK-N-BE(2) and BE(2)-C (n = 3); B, C Xenograft formation of SK-N-BE(2) cells (n = 6); D, E Xenograft formation of BE(2)-C cells (n = 6).

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Knockdown

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 6 IGF2BP3 regulated NB cell proliferation via reading m6A modification of MYCN. A IGF2BP3 could bind to MYCN RNA predicted by RBPsuite website tools; B The enrichment of IGF2BP3 in the mRNA of MYCN performed by RIP-qPCR assay in SK-N-BE(2) (n = 3); C The enrichment of IGF2BP3 in the mRNA of MYCN performed by RIP-qPCR assay in BE(2)-C (n = 3); D, E The m6A modification site of MYCN predicted by SRAMP website tools based on sequence-derived features, and primers designed for MeRIP-qPCR assay. F Obvious m6A modification of MYCN confirmed by MeRIP-qPCR, and knockdown of m6A writer METTL3 repressed MYCN m6A modification in SK-N-BE(2) (n = 3); G Obvious m6A modification of MYCN confirmed by MeRIP-qPCR, and knockdown of m6A writer METTL3 repressed MYCN m6A modification in BE(2)-C (n = 3); H The mRNA stability and degradation halftime of MYCN in SK-N-BE(2) treated by Actinomycin D (n = 3); I The mRNA stability and degradation halftime of MYCN in BE(2)-C treated by Actinomycin D (n = 3).

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Sequencing, Derivative Assay, Knockdown

Journal: Cell death discovery

Article Title: RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation.

doi: 10.1038/s41420-023-01449-3

Figure Lengend Snippet: Fig. 7 N-myc directly promotes the IGF2BP3 expression in NB cells. A qRT-PCR analysis of the expression level of IGF2BP3 mRNA in SK-N- BE(2) (n = 3); B qRT-PCR analysis of the expression level of MYCN mRNA in SK-N-BE(2) (n = 3); C qRT-PCR analysis of the expression level of IGF2BP3 mRNA in BE(2)-C (n = 3); D qRT-PCR analysis of the expression level of MYCN mRNA in BE(2)-C (n = 3); E Schematic illustration of E-boxes (CANNTG) element in IGF2BP3 promoter; F, G Analysis of the effect of N-myc on IGF2BP3 promoter by ChIP-qPCR (n = 3); H Analysis of the targeting effect of N-myc on IGF2BP3 promoter by luciferase reporter assay (n = 3); I Schematic diagram of a positive feedback loop between RNA N6-methyladenosine reader IGF2BP3 and MYCN facilitates NB proliferation.

Article Snippet: Subsequently, the corresponding antibodies were used to label IGF2BP3 (1:100, Cat No. 14642-1-AP, Proteintech Group, Inc.) or METTL3 (1:200, Cat No. 15073-1-AP, Proteintech Group, Inc.).

Techniques: Expressing, Quantitative RT-PCR, ChIP-qPCR, Luciferase, Reporter Assay

Journal: Analytical and bioanalytical chemistry

Article Title: Simultaneous measurement of total Estradiol and Testosterone in human serum by isotope dilution liquid chromatography tandem mass spectrometry

doi: 10.1007/s00216-017-0529-x

Figure Lengend Snippet: Steroid hormones used for interference analysis. Their Molecular weight and source of materials are provided.

Article Snippet: 5a-Dihydrotestosterone (DHT) , 290.44 , Cerilliant (Round Rock, TX).

Techniques: Molecular Weight

Journal: Molecular Pharmaceutics

Article Title: Role of the Phospholipase A 2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells

doi: 10.1021/mp500174p

Figure Lengend Snippet: Effect of PLA2R1 knockdown on chemotherapeutic-induced toxicity in PC-3 cells. Cells were treated with docetaxel (A), cisplatin (B), or Dox (C) for 72 h. MTT assays were used to determine the effect of knocking down PLA2R1 on chemotherapeutic-induced cytotoxicity. The effect of PLA2R1 on doxorubicin-induced toxicity was further assessed at 72 h using phase contrast microscopy at 10× magnification (D). Data in panels A–C are represented as the mean ± SD of at least three separate experiments ( n = 3/study). Data in panel D are indicative of at least three separate experiments.

Article Snippet: Doxorubicin (Dox) was purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Knockdown, Microscopy

Journal: Molecular Pharmaceutics

Article Title: Role of the Phospholipase A 2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells

doi: 10.1021/mp500174p

Figure Lengend Snippet: Effect of PLA2R1 knockdown on the toxicity of doxorubicin encapsulated in SSL and SPRL in PC-3 cells. PLA2R1 knockdown cells and those expressing scrambled shRNA were treated with 2.5 μM concentrations of Dox encapsulated in SSL or SPRL. MTT assays (A) and phase contrast microscopy at 40× magnification (B) were used to determine the effect of PLA2R1 knockdown on cytotoxicity. Data in panel A are represented as the mean ± SEM of at least three separate experiments ( n = 3/study). *Indicates a significant difference ( p < 0.05) as compared to cells transfected with scrambled shRNA. Data in panel E are indicative of at least three separate experiments.

Article Snippet: Doxorubicin (Dox) was purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Knockdown, Expressing, shRNA, Microscopy, Transfection

Journal: Molecular Pharmaceutics

Article Title: Role of the Phospholipase A 2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells

doi: 10.1021/mp500174p

Figure Lengend Snippet: Effect of PLA2R1 knockdown on DiO and doxorubicin uptake from SSL and SPRL in PC-3 cells. PC-3 cells were treated with liposomes containing Dox and DiO for 24 to 72 h. The efficiency of DiO and drug uptake via SSL (A, B) and SPRL (C, D) was quantified using flow cytometry. Data are represented as the mean ± SEM of at least three separate experiments ( n = 3/study). *Indicates a significant difference ( p < 0.05) as compared to cells expressing scrambled shRNA.

Article Snippet: Doxorubicin (Dox) was purchased from Toronto Research Chemicals (North York, ON, Canada).

Techniques: Knockdown, Liposomes, Flow Cytometry, Expressing, shRNA